Silence Therapeutics (SLN) Common Equity: 2019-2025
Historic Common Equity for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to $74.1 million.
- Silence Therapeutics' Common Equity fell 41.54% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 41.54%. This contributed to the annual value of $134.0 million for FY2024, which is 509.39% up from last year.
- Per Silence Therapeutics' latest filing, its Common Equity stood at $74.1 million for Q3 2025, which was down 21.34% from $94.2 million recorded in Q2 2025.
- Silence Therapeutics' 5-year Common Equity high stood at $156.8 million for Q1 2024, and its period low was -$6.0 million during Q2 2022.
- Over the past 3 years, Silence Therapeutics' median Common Equity value was $103.4 million (recorded in 2025), while the average stood at $90.3 million.
- In the last 5 years, Silence Therapeutics' Common Equity skyrocketed by 825.94% in 2024 and then crashed by 41.54% in 2025.
- Silence Therapeutics' Common Equity (Quarterly) stood at $11.5 million in 2021, then soared by 125.26% to $25.9 million in 2022, then decreased by 15.05% to $22.0 million in 2023, then surged by 509.39% to $134.0 million in 2024, then slumped by 41.54% to $74.1 million in 2025.
- Its Common Equity stands at $74.1 million for Q3 2025, versus $94.2 million for Q2 2025 and $112.7 million for Q1 2025.